274 related articles for article (PubMed ID: 19098407)
21. Clinical relevance of resistance to antifungals.
Rodriguez-Tudela JL; Alcazar-Fuoli L; Cuesta I; Alastruey-Izquierdo A; Monzon A; Mellado E; Cuenca-Estrella M
Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S111-3. PubMed ID: 19013333
[TBL] [Abstract][Full Text] [Related]
22. [Microbial spectrum in surgical infections based on a microbiological routine monitoring over the 10-year period from 1995 to 2004].
Mroczkowski P; Lauf H; Lippert H; König W; Meyer F
Zentralbl Chir; 2009 Jun; 134(3):226-30. PubMed ID: 19536716
[TBL] [Abstract][Full Text] [Related]
23. Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province, China.
Xie L; Zhai H; Zhao J; Sun S; Shi W; Dong X
Am J Ophthalmol; 2008 Aug; 146(2):260-265. PubMed ID: 18547535
[TBL] [Abstract][Full Text] [Related]
24. [Epidemiological study of invasive nosocomial candidiasis in 2 teaching hospitals in Beijing].
Cao B; Wang H; Wu L; Sun WJ; Li F; Liu YM
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1970-3. PubMed ID: 19062737
[TBL] [Abstract][Full Text] [Related]
25. In vitro efficacy of a buffered chelating solution as an antimicrobial potentiator for antifungal drugs against fungal pathogens obtained from horses with mycotic keratitis.
Weinstein WL; Moore PA; Sanchez S; Dietrich UM; Wooley RE; Ritchie BW
Am J Vet Res; 2006 Apr; 67(4):562-8. PubMed ID: 16579746
[TBL] [Abstract][Full Text] [Related]
26. Changing epidemiology of systemic fungal infections.
Richardson M; Lass-Flörl C
Clin Microbiol Infect; 2008 May; 14 Suppl 4():5-24. PubMed ID: 18430126
[TBL] [Abstract][Full Text] [Related]
27. Characteristics of pathogenic fungi and antifungal therapy in cystic fibrosis.
Müller FM; Seidler M
Expert Rev Anti Infect Ther; 2010 Aug; 8(8):957-64. PubMed ID: 20695750
[TBL] [Abstract][Full Text] [Related]
28. Microbial profile and drug resistance of Candida strains isolated from the blood of children: an 11-year study.
Małafiej E; Adamiec AC; Tworzyańska U
Mycoses; 2009 Mar; 52(2):149-53. PubMed ID: 18627468
[TBL] [Abstract][Full Text] [Related]
29. Oral yeast carriage in HIV-infected and non-infected populations in Rosario, Argentina.
Luque AG; Biasoli MS; Tosello ME; Binolfi A; Lupo S; Magaró HM
Mycoses; 2009 Jan; 52(1):53-9. PubMed ID: 18498298
[TBL] [Abstract][Full Text] [Related]
30. Detection and antifungal susceptibility testing of oral Candida dubliniensis from human immunodeficiency virus-infected patients.
Chunchanur SK; Nadgir SD; Halesh LH; Patil BS; Kausar Y; Chandrasekhar MR
Indian J Pathol Microbiol; 2009; 52(4):501-4. PubMed ID: 19805956
[TBL] [Abstract][Full Text] [Related]
31. [Invasive fungal disease in patients from five hospitals in the Valparaíso region, Chile: 2004 to 2009].
Cruz Ch R; Piontelli L E
Rev Chilena Infectol; 2011 Apr; 28(2):123-9. PubMed ID: 21720691
[TBL] [Abstract][Full Text] [Related]
32. Recent experience with fungaemia: change in species distribution and azole resistance.
Chakrabarti A; Chatterjee SS; Rao KL; Zameer MM; Shivaprakash MR; Singhi S; Singh R; Varma SC
Scand J Infect Dis; 2009; 41(4):275-84. PubMed ID: 19229762
[TBL] [Abstract][Full Text] [Related]
33. Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections.
Lewis RE
Am J Ther; 2012 Jan; 19(1):51-63. PubMed ID: 21248618
[TBL] [Abstract][Full Text] [Related]
34. Time to positive culture and identification for Candida blood stream infections.
Fernandez J; Erstad BL; Petty W; Nix DE
Diagn Microbiol Infect Dis; 2009 Aug; 64(4):402-7. PubMed ID: 19446982
[TBL] [Abstract][Full Text] [Related]
35. [Analysis of the pathogenic characteristics of fungal bloodstream infection in severe burn patients].
Zhang C; Gong YL; Luo XQ; Liu MX; Shi YL; Liu TF; Li HY; Peng YZ
Zhonghua Shao Shang Za Zhi; 2020 Jan; 36(1):37-41. PubMed ID: 32023716
[No Abstract] [Full Text] [Related]
36. Fungal osteoarticular infections in patients treated at a comprehensive cancer centre: a 10-year retrospective review.
Kumashi PR; Safdar A; Chamilos G; Chemaly RF; Raad II; Kontoyiannis DP
Clin Microbiol Infect; 2006 Jul; 12(7):621-6. PubMed ID: 16774557
[TBL] [Abstract][Full Text] [Related]
37. Current status of antifungal resistance and its impact on clinical practice.
Alcazar-Fuoli L; Mellado E
Br J Haematol; 2014 Aug; 166(4):471-84. PubMed ID: 24749533
[TBL] [Abstract][Full Text] [Related]
38. [Drug resistance in the treatment of invasive fungal infections].
Nordøy I; Gaustad P
Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2607-11. PubMed ID: 19023376
[TBL] [Abstract][Full Text] [Related]
39. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
Leroy O; Gangneux JP; Montravers P; Mira JP; Gouin F; Sollet JP; Carlet J; Reynes J; Rosenheim M; Regnier B; Lortholary O;
Crit Care Med; 2009 May; 37(5):1612-8. PubMed ID: 19325476
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS; Lee TJ; Kim J; Kim D
Clin Ther; 2009 May; 31(5):1105-15; discussion 1066-8. PubMed ID: 19539111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
